Spary 3

Battling cancer is its own challenge.
But when you’re also fighting the chronic pain associated with cancer, this challenge can be overwhelming.

That’s why researchers are investigating a new therapy that may help relieve chronic cancer pain. The SPRAY III study is a Phase 3 clinical study for patients whose chronic cancer pain is not totally relieved by their current pain medication. The SPRAY III study will determine whether Sativex®(nabiximols) is effective in helping manage chronic cancer pain in addition to opiate pain medication. Qualified participants will receive study-related medical evaluations, tests, and the investigational medication or placebo (a mouth spray that does not contain any active medication). After completion of the 9-week study, you may have the option to enter an extension study, which provides continued availability of Sativex®.

You may be eligible for the SPRAY III clinical research study if you:

Have a clinical diagnosis of chronic cancer pain
Are currently taking opiate treatments, such as morphine and oxycodone, but still having trouble managing your pain
Do not have any known or suspected drug or alcohol dependency disorders
Are 18 years of age or older

Additional requirements for study eligibility will be assessed by the study doctor.

See if the spray 3 study is right for you